WallStreetZenWallStreetZen

NASDAQ: MRVI
Maravai Lifesciences Holdings Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

MRVI past revenue growth

How has MRVI's revenue growth performed historically?
Company
-67.28%
Industry
148.64%
Market
17.33%
MRVI's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
MRVI's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
MRVI's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

MRVI earnings and revenue history

Current Revenue
$288.9M
Current Earnings
-$119.0M
Current Profit Margin
-41.2%

MRVI Return on Equity

Current Company
-24.1%
Current Industry
-63.5%
Current Market
188%
MRVI's Return on Equity (-24.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when MRVI announces earnings.

MRVI Return on Assets

Current Company
-5.7%
Current Industry
2.9%
MRVI is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

MRVI Return on Capital Employed

Current Company
48.78%
Current Industry
19.5%
MRVI has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MRVI vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
MRVI$288.95M$731.76M-$119.03M+18.47%N/A
GLPG$260.57M$240.55M$230.11M-5.51%+5.12%
PTCT$937.82M-$320.51M-$626.60M+28.78%N/A
BEAM$377.71M-$111.15M-$132.53M+1,103.57%N/A
NAMS$15.32M-$192.24M-$192.32M-85.67%N/A
View Top Biotech Stocks

MRVI earnings dates

Next earnings date
May 8, 2024

Maravai Lifesciences Holdings Earnings & Revenue FAQ

What were MRVI's earnings last quarter?

On Invalid Date, Maravai Lifesciences Holdings (NASDAQ: MRVI) reported Q4 2023 earnings per share (EPS) of -$0.80, up 385.71% year over year. Total Maravai Lifesciences Holdings earnings for the quarter were -$105.96 million. In the same quarter last year, Maravai Lifesciences Holdings's earnings per share (EPS) was $0.28.

If you're new to stock investing, here's how to buy Maravai Lifesciences Holdings stock.

What was MRVI's earnings growth in the past year?

As of Q2 2024, Maravai Lifesciences Holdings's earnings has grown year over year. Maravai Lifesciences Holdings's earnings in the past year totalled -$119.03 million.

What is MRVI's earnings date?

Maravai Lifesciences Holdings's earnings date is Invalid Date. Add MRVI to your watchlist to be reminded of MRVI's next earnings announcement.

What was MRVI's revenue last quarter?

On Invalid Date, Maravai Lifesciences Holdings (NASDAQ: MRVI) reported Q4 2023 revenue of $74.14 million up 63.78% year over year. In the same quarter last year, Maravai Lifesciences Holdings's revenue was $204.71 million.

What was MRVI's revenue growth in the past year?

As of Q2 2024, Maravai Lifesciences Holdings's revenue has grown -67.28% year over year. This is 215.91 percentage points lower than the US Biotechnology industry revenue growth rate of 148.64%. Maravai Lifesciences Holdings's revenue in the past year totalled $288.95 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.